SG11201906616VA - Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants - Google Patents
Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutantsInfo
- Publication number
- SG11201906616VA SG11201906616VA SG11201906616VA SG11201906616VA SG11201906616VA SG 11201906616V A SG11201906616V A SG 11201906616VA SG 11201906616V A SG11201906616V A SG 11201906616VA SG 11201906616V A SG11201906616V A SG 11201906616VA SG 11201906616V A SG11201906616V A SG 11201906616VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- nasal
- composition
- silicon dioxide
- air pollutants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762448556P | 2017-01-20 | 2017-01-20 | |
US201762517369P | 2017-06-09 | 2017-06-09 | |
PCT/IB2018/050349 WO2018134783A1 (en) | 2017-01-20 | 2018-01-19 | Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906616VA true SG11201906616VA (en) | 2019-08-27 |
Family
ID=61094560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906616VA SG11201906616VA (en) | 2017-01-20 | 2018-01-19 | Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants |
Country Status (11)
Country | Link |
---|---|
US (1) | US10729646B2 (ko) |
EP (1) | EP3570848B1 (ko) |
KR (1) | KR20190109452A (ko) |
CN (1) | CN110461340A (ko) |
CA (1) | CA3050361A1 (ko) |
ES (1) | ES2948282T3 (ko) |
HU (1) | HUE063346T2 (ko) |
MX (2) | MX2019008656A (ko) |
RU (1) | RU2019123307A (ko) |
SG (1) | SG11201906616VA (ko) |
WO (1) | WO2018134783A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019517590A (ja) | 2016-06-03 | 2019-06-24 | エム エ ペ ファルマ アクチェンゲゼルシャフト | 多孔性賦形剤を含む経鼻用医薬組成物 |
RU2020126425A (ru) | 2018-01-11 | 2022-02-11 | М Эт П Фарма Аг | Лечение демиелинизирующих заболеваний |
KR20210028409A (ko) | 2019-09-04 | 2021-03-12 | 엘지디스플레이 주식회사 | 유기 화합물, 이를 포함하는 유기발광다이오드 및 유기발광장치 |
US20210275989A1 (en) * | 2020-03-05 | 2021-09-09 | Performance Labs PTE. LTD. | Functional materials and devices for reducing toxic pollutants |
US20240009149A1 (en) * | 2020-11-19 | 2024-01-11 | Acousia Therapeutics Gmbh | Non-aqueous gel composition |
CN114653172B (zh) * | 2022-03-15 | 2023-11-14 | 江苏理工学院 | 一种协同脱除VOCs和Hg0的方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4546882A (en) | 1983-02-07 | 1985-10-15 | American Can Company | Package having oil-containing product |
US5002597A (en) * | 1989-04-03 | 1991-03-26 | Invent Ag | Aerodynamic filter |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
DE19701912C1 (de) | 1997-01-10 | 1998-05-14 | Jenapharm Gmbh | Injizierbares Implantat |
DE10064950A1 (de) * | 2000-12-23 | 2002-07-11 | Impetus Ag Basel | Thixotropes Nasenspray |
US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
US7563451B2 (en) | 2003-07-22 | 2009-07-21 | Iowa State University Research Foundation, Inc. | Capped mesoporous silicates |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
US20070077309A1 (en) | 2005-09-30 | 2007-04-05 | Wong Patrick S | Banded controlled release nanoparticle active agent formulation dosage forms and methods |
DK2068825T3 (da) | 2006-10-04 | 2011-05-16 | M & P Patent Ag | Kontrolleret frisætningstilførselssystem til nasal påføring af neurotransmittere |
US8258137B2 (en) | 2008-01-29 | 2012-09-04 | Katholieke Universiteit Leuven | Process for release of biologically active species from mesoporous oxide systems |
KR101689635B1 (ko) | 2008-09-23 | 2016-12-26 | 라보라토리 스킨 케어, 인크. | 활성제 장입된 균일하고 강성이면서 구형의 나노다공성 인산칼슘 입자 및 그의 제조 방법과 그의 용도 |
JP2010083834A (ja) * | 2008-10-01 | 2010-04-15 | Naris Cosmetics Co Ltd | アレルゲン不活性化剤、及びそれを含有する化粧料。 |
JP2012506904A (ja) | 2008-10-28 | 2012-03-22 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 難水溶性成分のためのメソ多孔性材料賦形剤 |
CN103687587A (zh) * | 2011-05-13 | 2014-03-26 | 特利默生物医药有限公司 | 鼻内较低剂量强度睾酮凝胶制剂及其用于治疗性快感缺失病或性欲减退疾患的应用 |
US20130040922A1 (en) * | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
WO2012156820A1 (en) * | 2011-05-15 | 2012-11-22 | Trimel Pharmaceuticals Corp. | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
PT2819699T (pt) * | 2012-02-27 | 2019-08-21 | Bayer New Zealand Ltd | Composições de libertação controlada e os seus métodos de utilização |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
US20150290217A1 (en) | 2012-11-21 | 2015-10-15 | Trimel Biopharma Srl | Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt |
US9474720B2 (en) | 2013-11-04 | 2016-10-25 | BioPharmX, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
EP3193836A1 (en) | 2014-09-15 | 2017-07-26 | PharmaSol GmbH | Active-loaded particulate materials for topical administration |
CN107847433B (zh) * | 2015-08-04 | 2021-02-05 | 风之星医疗有限公司 | 鼻用组合物 |
WO2017042709A1 (en) * | 2015-09-09 | 2017-03-16 | King Abdullah University Of Science And Technology | Functionalized sio2 microspheres for extracting oil from produced water |
JP2019517590A (ja) | 2016-06-03 | 2019-06-24 | エム エ ペ ファルマ アクチェンゲゼルシャフト | 多孔性賦形剤を含む経鼻用医薬組成物 |
-
2018
- 2018-01-19 EP EP18702341.1A patent/EP3570848B1/en active Active
- 2018-01-19 CA CA3050361A patent/CA3050361A1/en active Pending
- 2018-01-19 HU HUE18702341A patent/HUE063346T2/hu unknown
- 2018-01-19 ES ES18702341T patent/ES2948282T3/es active Active
- 2018-01-19 WO PCT/IB2018/050349 patent/WO2018134783A1/en active Application Filing
- 2018-01-19 SG SG11201906616VA patent/SG11201906616VA/en unknown
- 2018-01-19 RU RU2019123307A patent/RU2019123307A/ru unknown
- 2018-01-19 CN CN201880019834.3A patent/CN110461340A/zh active Pending
- 2018-01-19 KR KR1020197023918A patent/KR20190109452A/ko not_active Application Discontinuation
- 2018-01-19 MX MX2019008656A patent/MX2019008656A/es unknown
- 2018-06-22 US US16/016,335 patent/US10729646B2/en active Active
-
2019
- 2019-07-19 MX MX2022006529A patent/MX2022006529A/es unknown
Also Published As
Publication number | Publication date |
---|---|
RU2019123307A3 (ko) | 2021-05-24 |
US20180296472A1 (en) | 2018-10-18 |
CN110461340A (zh) | 2019-11-15 |
ES2948282T3 (es) | 2023-09-07 |
MX2022006529A (es) | 2022-07-11 |
RU2019123307A (ru) | 2021-02-20 |
EP3570848A1 (en) | 2019-11-27 |
HUE063346T2 (hu) | 2024-01-28 |
CA3050361A1 (en) | 2018-07-26 |
EP3570848C0 (en) | 2023-06-07 |
US10729646B2 (en) | 2020-08-04 |
MX2019008656A (es) | 2019-11-21 |
EP3570848B1 (en) | 2023-06-07 |
WO2018134783A1 (en) | 2018-07-26 |
KR20190109452A (ko) | 2019-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906616VA (en) | Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201810872UA (en) | Composition and method for reducing neutropenia | |
SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |